longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

TherapeuticsMD Inc. Stock Underperforms Wednesday When Compared To Competitors

MarketWatch Automated
Jul 1, 2026 at 09:29 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

TherapeuticsMD Inc. (TXMD) shares fell 2.26% to $2.16 on Wednesday, underperforming competitors like AbbVie during a broader market decline. This marks the second consecutive day of losses for the stock, which remains 26.78% below its 52-week high. Trading volume was below the 50-day average.

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of TherapeuticsMD Inc. (TXMD) shed 2.26% to $2.16 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 0.66% to 26,040.03 and Dow Jones Industrial Average falling 0.03% to 52,305.24.

This was the stock's second consecutive day of losses.

TherapeuticsMD Inc. closed 26.78% below its 52-week high of $2.95, which the company achieved on January 27th.

The stock underperformed when compared to some of its competitors Wednesday, as AbbVie Inc. (ABBV) fell 0.23% to $251.06.

Trading volume (36,071) remained 5,047 below its 50-day average volume of 41,118.

Data source: Dow Jones Market Data, FactSet. Data compiled July 1, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-01-26 1729ET

Login to unlock525characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Sep 8, 2026 at 12:14 PMAI-era DCI: Beyond the chip, compete as a network. Is there a China play?

Related Stocks

Therapeutics MD

Therapeutics MD

USTXMD

+1.40%

Abbvie

Abbvie

USABBV

Factset Research

Factset Research

USFDS

LongbridgeAI